Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Zusammenfassung

Am J Respir Crit Care Med. 2025 Jan 1;211(1):15–33. doi: 10.1164/rccm.202410-2096ST Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Jussi J Saukkonen Jussi J Saukkonen Find articles by Jussi J Saukkonen *,✉, Raquel Duarte Raquel Duarte Find articles by Raquel Duarte *, Sonal S Munsiff Sonal S Munsiff Find articles by Sonal S Munsiff *, Carla A Winston Carla A Winston Find articles by Carla A Winston *, Manoj J

Kerninformationen

Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America Author information Article notes Copyright and License information ✉Correspondence and requests for reprints should be addressed to Jussi J. Saukkonen, M.D., A.T.S.F., Division of Pul...

Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and ...

Centers for Disease Control and Prevention (CDC)/European Respiratory Society (ERS)/Infectious Diseases Society (IDSA) guidelines? Recommendation: In people aged 12 years or older with drug-susceptible pulmonary tuberculosis, we conditionally recommend the use of a 4-month regimen of isoniazid, rifa...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen